June 8, 2020 / 8:18 PM / a month ago

BRIEF-Gbt Plans To Seek Expanded Labeling For Oxbryta® For Sickle Cell Disease

June 8 (Reuters) - Global Blood Therapeutics Inc:

* GBT ANNOUNCES PLANS TO SEEK EXPANDED LABELING FOR OXBRYTA® (VOXELOTOR) TO TREAT CHILDREN AGES 4 TO 11 YEARS WITH SICKLE CELL DISEASE

* GLOBAL BLOOD THERAPEUTICS INC - NEW DRUG APPLICATION SUBMISSION PLANNED BY MID-2021

* GLOBAL BLOOD THERAPEUTICS - TO SUBMIT NDA FOR OXBRYTA FOR TREATMENT OF SCD IN CHILDREN AGES 4 TO 11 YEARS UNDER FDA’S ACCELERATED APPROVAL PATHWAY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below